Skip to main content
VYNE Therapeutics Inc. logo

VYNE Therapeutics Inc. — Investor Relations & Filings

Ticker · VYNE ISIN · US92941V1008 US Manufacturing
Open in API
Filings indexed 608 across all filing types
Latest filing 2021-06-07 Proxy Solicitation & In…
Country US United States of America
Listing US VYNE

About VYNE Therapeutics Inc.

https://vynetherapeutics.com/

VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company's primary objective is to address unmet medical needs by advancing a pipeline of novel drug candidates. VYNE's approach centers on innovating beyond traditional assumptions to find improved solutions for patients with complex inflammatory and immunological diseases.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about voting items such as election of directors, ratification of auditors, and approval of amendments to the certificate of incorporation. The document is not the actual Annual Report or financial statements but rather materials sent to shareholders to provide information and request votes for the meeting. Therefore, it fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is 4632 characters, which is consistent with a proxy statement or solicitation material rather than a full report.
2021-06-07 English
DEF 14A
Proxy Solicitation & Information Statement
2021-06-07 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The content specifically details the departure of a CFO and the appointment of an interim CFO, including terms of employment and severance. This matches the description of announcements related to changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, it fits best under the category for Board/Management Information (MANG). The document length is 7976 characters, which is sufficient to contain detailed information rather than a brief announcement or certification. Hence, the classification is MANG with high confidence.
2021-06-07 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-02 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-02 English
FORM 4 SUBMISSION
Director's Dealing
2021-05-27 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.